146 related articles for article (PubMed ID: 34664265)
1. Population-based cohort study of the efficacy of brentuximab vedotin in relapsed systemic anaplastic large-cell lymphoma using Public Health England data.
Halligan SJ; Grainge MJ; Martinez-Calle N; Fox CP; Bishton MJ
Br J Haematol; 2022 Feb; 196(4):932-938. PubMed ID: 34664265
[TBL] [Abstract][Full Text] [Related]
2. Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study.
Izutsu K; Ogura M; Tobinai K; Hatake K; Sakamoto S; Nishimura M; Hoshino M
Int J Hematol; 2021 Mar; 113(3):404-412. PubMed ID: 33392974
[TBL] [Abstract][Full Text] [Related]
3. Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotin.
Chihara D; Wong S; Feldman T; Fanale MA; Sanchez L; Connors JM; Savage KJ; Oki Y
Hematol Oncol; 2019 Feb; 37(1):35-38. PubMed ID: 30209819
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients.
Gandolfi L; Pellegrini C; Casadei B; Stefoni V; Broccoli A; Tonialini L; Morigi A; Argnani L; Zinzani PL
Oncologist; 2016 Dec; 21(12):1436-1441. PubMed ID: 27486201
[TBL] [Abstract][Full Text] [Related]
5. Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma.
Ishizawa K; Yanai T
Adv Ther; 2019 Oct; 36(10):2679-2696. PubMed ID: 31392578
[TBL] [Abstract][Full Text] [Related]
6. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of brentuximab vedotin for relapsed or refractory systemic anaplastic large-cell lymphoma in China.
Liu J; Zheng L; Chuang LH
J Med Econ; 2022; 25(1):99-107. PubMed ID: 34927526
[TBL] [Abstract][Full Text] [Related]
8. Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma.
Song Y; Guo Y; Huang H; Li W; Ke X; Feng J; Xu W; Miao H; Kinley J; Song G; Dai Y; Wang H; Zhu J
Expert Rev Hematol; 2021 Sep; 14(9):867-875. PubMed ID: 34275403
[TBL] [Abstract][Full Text] [Related]
9. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma.
Pro B; Advani R; Brice P; Bartlett NL; Rosenblatt JD; Illidge T; Matous J; Ramchandren R; Fanale M; Connors JM; Fenton K; Huebner D; Pinelli JM; Kennedy DA; Shustov A
Blood; 2017 Dec; 130(25):2709-2717. PubMed ID: 28974506
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of brentuximab vedotin (SGN-35) in Japanese children with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma.
Koga Y; Sekimizu M; Iguchi A; Kada A; Saito AM; Asada R; Mori T; Horibe K
Int J Hematol; 2020 May; 111(5):711-718. PubMed ID: 31960285
[TBL] [Abstract][Full Text] [Related]
11. Brentuximab vedotin in T-cell lymphoma.
Van Der Weyden C; Dickinson M; Whisstock J; Prince HM
Expert Rev Hematol; 2019 Jan; 12(1):5-19. PubMed ID: 30526166
[TBL] [Abstract][Full Text] [Related]
12. FDA Approval Summary: Brentuximab Vedotin in First-Line Treatment of Peripheral T-Cell Lymphoma.
Richardson NC; Kasamon YL; Chen H; de Claro RA; Ye J; Blumenthal GM; Farrell AT; Pazdur R
Oncologist; 2019 May; 24(5):e180-e187. PubMed ID: 30914464
[TBL] [Abstract][Full Text] [Related]
13. Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort.
Martinez-Calle N; Kirkwood AA; Lamb M; Smith A; Khwaja J; Manos K; Shrubsole C; Gray N; Lewis K; Tivey A; Bishton MJ; Hawkes E; Ahearne MJ; Osborne W; Collins GP; Illidge T; Linton KM; Cwynarski K; Burton C; Fox CP
Adv Ther; 2021 Jul; 38(7):3789-3802. PubMed ID: 34037958
[TBL] [Abstract][Full Text] [Related]
14. Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma.
Broccoli A; Pellegrini C; Di Rocco A; Puccini B; Patti C; Gini G; Mannina D; Tani M; Rusconi C; Romano A; Vanazzi A; Botto B; Carlo-Stella C; Hohaus S; Musto P; Mazza P; Molica S; Corradini P; Fama A; Gaudio F; Merli M; Gravetti A; Gritti G; Arcari A; Tosi P; Liberati AM; Pinto A; Pavone V; Gherlinzoni F; Naso V; Volpetti S; Trentin L; Goldaniga MC; Bonfichi M; De Renzo A; Schiavotto C; Spina M; Storti S; Carella AM; Stefoni V; Argnani L; Zinzani PL
Haematologica; 2017 Nov; 102(11):1931-1935. PubMed ID: 28775121
[TBL] [Abstract][Full Text] [Related]
15. Brentuximab vedotin as a salvage treatment for relapsed and refractory Hodgkin lymphoma patients in Taiwan.
Tien FM; Tsai CH; Liu JH; Lin CT
J Formos Med Assoc; 2019 Oct; 118(10):1466-1470. PubMed ID: 31337522
[TBL] [Abstract][Full Text] [Related]
16. Isolated Central Nervous System Progression During Systemic Treatment With Brentuximab Vedotin Monotherapy in a Pediatric Patient With Recurrent ALK-negative Anaplastic Large Cell Lymphoma.
Kim Y; Sudo A; Oyama R; Keino D; Tomizawa D; Kato M; Osumi T; Mori T
J Pediatr Hematol Oncol; 2021 Aug; 43(6):e864-e866. PubMed ID: 32769561
[TBL] [Abstract][Full Text] [Related]
17. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin.
Oregel KZ; Everett E; Zhang X; Nagaraj G
Expert Rev Anticancer Ther; 2016; 16(3):279-83. PubMed ID: 26809026
[TBL] [Abstract][Full Text] [Related]
18. Brentuximab Vedotin Retreatment in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma or Peripheral T-Cell Lymphoma: A Retrospective United States Claims Analysis.
Sano D; Liu N; Knowles S; MacEwan JP; Wang S; Wogen J; Yu KS; Lee ST
Curr Oncol; 2024 May; 31(5):2598-2609. PubMed ID: 38785476
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous Anaplastic Large-Cell Lymphoma with Dramatic Response to Brentuximab Vedotin.
Şahin M; Miskioğlu M; İnanır I; Akar H; Neşe N; Temiz P; Aydoğdu İ
Turk J Haematol; 2021 Feb; 38(1):85-87. PubMed ID: 33504137
[No Abstract] [Full Text] [Related]
20. Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature.
Zinzani PL; Sasse S; Radford J; Shonukan O; Bonthapally V
Crit Rev Oncol Hematol; 2015 Sep; 95(3):359-69. PubMed ID: 25964164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]